McKesson Corporation (NYSE:MCK - Free Report) - Zacks Research boosted their Q3 2026 earnings per share estimates for McKesson in a note issued to investors on Wednesday, August 27th. Zacks Research analyst Team now expects that the company will earn $9.68 per share for the quarter, up from their previous estimate of $9.56. The consensus estimate for McKesson's current full-year earnings is $32.77 per share. Zacks Research also issued estimates for McKesson's Q4 2026 earnings at $10.61 EPS, FY2026 earnings at $37.12 EPS and FY2028 earnings at $46.77 EPS.
McKesson (NYSE:MCK - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $8.26 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.33 by ($0.07). The company had revenue of $97.83 billion for the quarter, compared to analyst estimates of $95.93 billion. McKesson had a negative return on equity of 196.66% and a net margin of 0.84%.The company's quarterly revenue was up 23.4% compared to the same quarter last year. During the same period in the prior year, the company earned $7.88 EPS.
Several other analysts have also issued reports on MCK. Wells Fargo & Company increased their target price on McKesson from $766.00 to $772.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 13th. Cowen reissued a "buy" rating on shares of McKesson in a report on Thursday, August 7th. Wall Street Zen lowered McKesson from a "strong-buy" rating to a "buy" rating in a report on Sunday, July 13th. Evercore ISI increased their target price on McKesson from $760.00 to $800.00 and gave the stock an "outperform" rating in a report on Wednesday, July 9th. Finally, Morgan Stanley reaffirmed an "overweight" rating and issued a $810.00 target price (up previously from $770.00) on shares of McKesson in a report on Wednesday, July 16th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $725.10.
View Our Latest Analysis on MCK
McKesson Stock Down 0.6%
Shares of MCK traded down $4.42 during trading hours on Monday, hitting $687.03. 472,767 shares of the company were exchanged, compared to its average volume of 808,316. The company has a market cap of $85.45 billion, a price-to-earnings ratio of 27.39, a P/E/G ratio of 1.37 and a beta of 0.51. McKesson has a fifty-two week low of $464.42 and a fifty-two week high of $737.89. The firm's fifty day moving average is $699.12 and its 200 day moving average is $690.52.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the company. Oppenheimer Asset Management Inc. lifted its stake in shares of McKesson by 54.0% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 4,541 shares of the company's stock valued at $3,056,000 after acquiring an additional 1,592 shares during the last quarter. Dynamic Advisor Solutions LLC raised its position in McKesson by 16.6% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 778 shares of the company's stock worth $524,000 after purchasing an additional 111 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its position in McKesson by 18.9% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 23,033 shares of the company's stock worth $15,501,000 after purchasing an additional 3,659 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in McKesson by 4.3% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 183,258 shares of the company's stock worth $123,332,000 after purchasing an additional 7,556 shares during the last quarter. Finally, LPL Financial LLC raised its position in McKesson by 12.8% during the 1st quarter. LPL Financial LLC now owns 155,946 shares of the company's stock worth $104,950,000 after purchasing an additional 17,750 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors.
Insiders Place Their Bets
In other news, CEO Brian S. Tyler sold 19,371 shares of the stock in a transaction on Friday, July 11th. The stock was sold at an average price of $708.09, for a total value of $13,716,411.39. Following the completion of the transaction, the chief executive officer directly owned 27,872 shares in the company, valued at approximately $19,735,884.48. This represents a 41.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Napoleon B. Rutledge, Jr. sold 329 shares of the stock in a transaction on Friday, August 8th. The shares were sold at an average price of $663.67, for a total value of $218,347.43. Following the completion of the transaction, the chief accounting officer owned 657 shares of the company's stock, valued at $436,031.19. The trade was a 33.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 43,560 shares of company stock valued at $30,438,602 over the last quarter. 0.08% of the stock is owned by corporate insiders.
McKesson Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Wednesday, October 1st. Shareholders of record on Tuesday, September 2nd will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.5%. This is a boost from McKesson's previous quarterly dividend of $0.71. McKesson's dividend payout ratio (DPR) is 13.08%.
McKesson Company Profile
(
Get Free Report)
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.
Featured Articles
Before you consider McKesson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and McKesson wasn't on the list.
While McKesson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
